Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition
- 19 February 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (4) , 552-563
Abstract
Patients diagnosed with acute myeloid leukemia with complex karyotype (CK AML) have an adverse prognosis using current therapies, especially when accompanied by TP53 alterations. We hereby report the RNA-sequencing analysis of the 68 CK AML samples included in the Leucegene 415 patient cohort. We confirm the frequent occurrence of TP53 alterations in this subgroup and further characterize the allele expression profile and transcript alterations of this gene. We also document that the RAS pathway (N/KRAS, NF1, PTPN11, BRAF) is frequently altered in this disease. Targeted chemical interrogation of genetically characterized primary CK AML samples identifies Polo-Like Kinase 1 (PLK1) inhibitors as the most selective agents for this disease subgroup. TP53 status did not alter sensitivity to PLK1 inhibitors. Interestingly, CK AML specimens display a G2/M transcriptomic signature that includes higher expression levels of PLK1 and correlates with PLK1 inhibition sensitivity. Together, our results highlight vulnerability in CK AML. In line with these in vitro data, volasertib shows a strong anti-AML activity in xenotransplantation mouse models of human adverse AML. Considering that PLK1 inhibitors are currently being investigated clinically in AML and myelodysplastic syndromes, our results provide a new rationale for PLK1-directed therapy in patients with adverse cytogenetic AML. Key Points After loss of wild-type TP53 expression, the RAS pathway is the second most frequently altered pathway in the CK AML subgroup. Adverse primary human AML is sensitive to PLK1 inhibitors in vitro and in xenotransplantation mouse models. Visual AbstractKeywords
This publication has 57 references indexed in Scilit:
- Uncovering the role of p53 splice variants in human malignancy: a clinical perspectiveOncoTargets and Therapy, 2013
- A novel hierarchical prognostic model of AML solely based on molecular mutationsBlood, 2012
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcomeBlood, 2012
- Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the casesLeukemia, 2011
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer CellsMolecular Cancer Research, 2011
- The Isoforms of the p53 ProteinCold Spring Harbor Perspectives in Biology, 2009
- A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Proceedings of the National Academy of Sciences, 2009
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Heat Shock Protein 90 Regulates the Metaphase-Anaphase Transition in a Polo-Like Kinase-Dependent MannerCancer Research, 2004